Acadian Asset Management’s Travere Therapeutics TVTX Stock Holding History

Acadian Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$77K	Sell	2,624 -26,186	-91%	-$783K	﹤0.01%	1799
2025 Q4	$1.1M	Buy	+28,810	New	+$937K	﹤0.01%	1099
2024 Q4	–	Sell	-16,452	Closed	-$230K	–	2173
2024 Q3	$230K	Sell	16,452 -128,449	-89%	-$1.34M	﹤0.01%	1315
2024 Q2	$1.19M	Buy	144,901 +97,020	+203%	+$653K	﹤0.01%	939
2024 Q1	$368K	Buy	+47,881	New	+$404K	﹤0.01%	1075
2020 Q3	–	Sell	-9,674	Closed	-$198K	–	2357
2020 Q2	$198K	Sell	9,674 -12,954	-57%	-$206K	﹤0.01%	1491
2020 Q1	$331K	Sell	22,628 -11,945	-35%	-$180K	﹤0.01%	1067
2019 Q4	$491K	Buy	+34,573	New	+$442K	﹤0.01%	1075
2018 Q3	–	Sell	-29,418	Closed	-$801K	–	1795
2018 Q2	$801K	Buy	+29,418	New	+$783K	﹤0.01%	790
2015 Q4	–	Sell	-496	Closed	-$10K	–	1508
2015 Q3	$10K	Sell	496 -88,993	-99%	-$2.64M	﹤0.01%	1134
2015 Q2	$2.97M	Buy	+89,489	New	+$2.45M	0.01%	508

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management's TVTX Position: Q1 2026 in Review

Acadian Asset Management reduced its Travere Therapeutics (TVTX) stake by 91% in Q1 2026, selling an estimated $783K and leaving 2,624 shares worth $77K. The position accounts for ﹤0.01% of the portfolio, ranked #1799.

Acadian Asset Management first reported a position in TVTX in Q2 2015 and has held it in 11 quarters since. The position peaked at $2.97M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Acadian Asset Management held 2,624 shares of Travere Therapeutics worth $77K as of Q1 2026.
Acadian Asset Management sold 26,186 Travere Therapeutics shares in Q1 2026, an estimated $783K.
Travere Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1799 holding.
Acadian Asset Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 11 quarters since.
Acadian Asset Management's Travere Therapeutics position peaked at $2.97M in Q2 2015.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.